Difference between revisions of "SDB-001"
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | '''SDB-001 (2NE1, APICA, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide)''' is a drug that acts as a potent agonist for the | + | '''SDB-001 (2NE1, APICA, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide)''' is a drug that acts as a potent agonist for the cannabinoid receptors. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in synthetic cannabis. smoking blends, along with a related compound [[APINACA]] (sold as "AKB48"). Structurally it closely resembles cannabinoid compounds from patent WO 2003/035005 but with an indole core instead of indazole, and a simple pentyl chain on the indole 1-position. Pharmacological testing determined SDB-001 to have an IC50 of 175nM at CB1, only slightly less potent than JWH-018 which had an IC50 of 169nM, but over four times more tightly binding than AKB48, which had an IC50 of 824nM. The first published synthesis and pharmacological evaluation of SDB-001 revealed that it acts as a full agonist at [[CB1]] (EC50 = 34 nM) and [[CB2 receptor]]s (EC50 = 29 nM). Furthermore, SDB-001 possesses cannabis-like effects in rats, and appears to be less potent than [[JWH-018]] but more potent than [[THC]]. |
Latest revision as of 03:32, 14 April 2015
SDB-001 (2NE1, APICA, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide) is a drug that acts as a potent agonist for the cannabinoid receptors. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in synthetic cannabis. smoking blends, along with a related compound APINACA (sold as "AKB48"). Structurally it closely resembles cannabinoid compounds from patent WO 2003/035005 but with an indole core instead of indazole, and a simple pentyl chain on the indole 1-position. Pharmacological testing determined SDB-001 to have an IC50 of 175nM at CB1, only slightly less potent than JWH-018 which had an IC50 of 169nM, but over four times more tightly binding than AKB48, which had an IC50 of 824nM. The first published synthesis and pharmacological evaluation of SDB-001 revealed that it acts as a full agonist at CB1 (EC50 = 34 nM) and CB2 receptors (EC50 = 29 nM). Furthermore, SDB-001 possesses cannabis-like effects in rats, and appears to be less potent than JWH-018 but more potent than THC.
